Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05139914 · ClinicalTrials.gov registry record · Phase 4
Assessment of Dapagliflozin on Vascular Health in Patients With Type 2 Diabetes
A Phase 4 study, sponsored by Boston University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 4
- Enrollment target
NCT05139914: Clinical Trial Phase 4 study, sponsored by Boston University.
NCT05139914 is a Phase 4 study that was terminated before completion, run by Boston University. The registered enrollment target is 4 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05139914, a Phase 4 study, was terminated before completion, sponsored by Boston University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 4 participants
- Enrollment target
Study Summary
Patients with Type 2 Diabetes Mellitus (T2DM) have changes in blood vessel health that can lead to a higher chance of developing heart attacks or strokes. New medications for T2DM including dapagliflozin, which is a Sodium-Glucose Cotransporter-2 inhibitor (SGLT2) inhibitor, may help protect the heart and blood vessels. The overarching objective of this mechanistic study is to learn how a Sodium-Glucose Cotransporter-2 (SGT2) inhibitor, dapagliflozin, impacts vascular health in patients with Type 2 Diabetes Mellitus (T2DM). The investigators will compare the changes in vascular health to changes in endothelial cell (EC) phenotype including non-coding RNA (ncRNA) to develop evidence supporting the mechanism of cardiovascular benefit of SGLT2 inhibitors. This study will provide novel information regarding the mechanism of effects of novel treatments for endothelial function and vascular health in patients with T2DM to reduce cardiovascular (CV) risk. The research aims to assess the: * effects of dapagliflozin on EC phenotype. * impact of dapagliflozin on vasodilator function and additional measures of vascular health including arterial stiffness and circulating markers of vascular health.
Primary Outcome
Supine blood pressures were measure in triplicate after 10 minute rest period using Omron blood pressure cuff
Interventions
- OTHER Placebo
- DRUG Dapagliflozin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2022-05-31 |
| Est. Completion | 2025-02-04 |
| Phase | Phase 4 |
Why NCT05139914 stopped before completion
NCT05139914 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05139914 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05139914 about?
NCT05139914 is a clinical study titled "Assessment of Dapagliflozin on Vascular Health in Patients With Type 2 Diabetes". Patients with Type 2 Diabetes Mellitus (T2DM) have changes in blood vessel health that can lead to a higher chance of developing heart attacks or strokes. New medications for T2DM including dapagliflozin, which is a Sodium-Glucose Cotransporter-2 inhibitor (SGLT2) inhibitor, may help protect the hea...
What is the current status of trial NCT05139914?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 4 participants. The study started on 2022-05-31. Estimated completion is 2025-02-04.
What interventions are being tested in trial NCT05139914?
The interventions under investigation include: Placebo (OTHER), Dapagliflozin (DRUG).
Who is sponsoring clinical trial NCT05139914?
This trial is sponsored by Boston University, which has 185 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05139914's enrollment target sits among peer trials
4 1994th of 2000 higher than 6 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI